Genotyping Begins on NIDA’s Biorepository of Over 50,000 Samples – Affymetrix, BioRealm, & RUCDR Infinite Biologics Team ...
July 07 2015 - 6:30AM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX), BioRealm, LLC, and RUCDR
Infinite Biologics today announced a broad strategic alliance. This
alliance will leverage BioRealm's SmokeScreen® platform to genotype
the National Institute on Drug Abuse (NIDA) biorepository of more
than 50,000 samples, collected from human subjects studied in
NIDA-funded research. NIDA preserves these samples in a
biorepository at RUCDR Infinite Biologics, on the campus of Rutgers
University. The biorepository is maintained by RUCDR Infinite
Biologics and in part through collaboration with the BioProcessing
Solutions Alliance which was created by RUDCR Infinite Biologics
and BioStorage Technologies, the global leader in comprehensive
sample management.
Once the genetic information contained in these samples is made
available to researchers, it will be extremely valuable for
studying the link between genetic variations and addiction.
Detailed genetic information might, for example, be used by
researchers exploring how genetics influences patients’ individual
responses to treatment approaches.
To date, the genetic information contained in these samples has
been focused on specific targets and not collectively analyzed.
This strategic alliance makes it possible, for the first time ever,
to cost-efficiently analyze this valuable information. The genetic
information will be obtained by using BioRealm’s SmokeScreen®
array, developed in conjunction with NIDA’s Genetics Consortium and
Affymetrix. SmokeScreen® array is a genome-wide array with
research-driven focus on more than 1,000 addiction-related
genes.
BioRealm’s Co-Founder Dr. James Baurley remarked, “We are
extremely honored to have the help and support of Affymetrix and
RUCDR. Our SmokeScreen® technology provides a suite of genomic
research tools to scientists working on addiction – one of the
biggest public health threats. Because of our partners’ confidence
in our technology, it will be made available to scientific teams
around the world who are working on these critical health
issues.”
RUCDR Infinite Biologics’ Chief Operating Officer and Director
of Technology Development Dr. Andrew Brooks said, “Because of the
SmokeScreen® array, we have the ability to reveal genetic
information previously hidden in NIDA's samples. We have great
confidence in SmokeScreen® ‒ it is a validated platform that will
become a crucial tool in advancing addiction research and moving
the field towards personalized treatment.”
According to Dr. Frank R. Witney, President and Chief Executive
Officer of Affymetrix, “We are excited to be part of BioRealm’s
vision of improving human health by providing insight into the
genetics of tobacco-related illness. It was a pleasure to work with
BioRealm’s team of dedicated scientists to co-develop this
cutting-edge technology.”
About BioRealm LLC
BioRealm, a life sciences company headquartered in Monument,
Colorado, uses novel technology to provide end-to-end services for
researchers and product development teams, including study design,
data management, and data analysis. BioRealm’s cutting-edge
products and technologies support the research process, from
hypothesis to conclusion. BioRealm’s SmokeScreen® platform provides
researchers with unique insight into the genetics of addiction,
smoking behavior, and treatment approaches. Read more at
http://biorealmresearch.com/.
About RUCDR Infinite Biologics
RUCDR Infinite Biologics offers a complete and integrated
selection of biological sample processing, analysis and
biorepository services to government agencies, academic
institutions, foundations, and biotechnology and pharmaceutical
companies within the global scientific community. RUCDR provides
DNA, RNA, and cell lines with clinical data to hundreds of research
laboratories for studies on mental health and developmental
disorders, drug and alcohol abuse, diabetes and digestive, liver,
and kidney diseases. A unit of Rutgers University’s Human Genetics
Institute of New Jersey, RUCDR is the world’s largest
university-based biorepository. In 2012, a Bioprocessing Solutions
Alliance was created between RUCDR and BioStorage Technologies to
provide research companies and organizations with a
state-of-the-art scientific and technology infrastructure for the
delivery of advanced sample bioprocessing and biobanking solutions.
Read more at www.rucdr.org.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness.
Affymetrix provides leadership and support, partnering with
customers in pharmaceutical, diagnostic, and biotechnology
companies, as well as leading academic, government, and non-profit
research institutes in their quest to use biology for a better
world. More than 2,300 microarray systems have been shipped around
the world and more than 94,000 peer-reviewed papers have been
published citing Affymetrix technologies. Affymetrix is
headquartered in Santa Clara, California, and has manufacturing
facilities in Cleveland, Ohio, San Diego, Vienna, and Singapore.
Affymetrix has about 1,100 employees worldwide and maintains sales
and distribution operations across Europe, Asia, and Latin America.
For more information about Affymetrix, please visit
www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2014, and other SEC reports for subsequent
quarterly periods.
PLEASE NOTE: Affymetrix and the Affymetrix logo
trademarks are the property of Affymetrix, Inc. All other
trademarks are the property of their respective owners.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150707005447/en/
AffymetrixMedia
Contact:Mindy Lee-Olsen, 408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comInvestor Contact:Doug
Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.comorBioRealmBrian M. Malone,
202-904-1737brian.malone@biorealmresearch.comorRUCDR Infinite BiologicsEdward F. Tate III,
848-445-3153Director of Communicationsedward.tate@rutgers.edu
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024